文献速递术前评估与围术期医学疼痛医学

围术期加巴喷丁类药物治疗术后急性疼痛的系统综述与荟萃分析

Perioperative Use of Gabapentinoids for the Management of Postoperative Acute Pain: A Systematic Review and Meta-analysis.
PubMed 文献 · Anesthesiology · 2020-01-01

该系统综述纳入281项随机对照试验共24682例成人手术患者,评估围术期加巴喷丁类药物的镇痛效果与不良事件。结果显示加巴喷丁类药物在6、12、24、48小时降低术后疼痛强度,但均未达到最小重要差异阈值(100分制中10分),且对72小时疼痛、亚急性及慢性疼痛无影响,不增加术后恶心呕吐风险但增加头晕和视觉障碍。结论不支持成人术后疼痛常规使用加巴喷丁或普瑞巴林。

要点

  • 加巴喷丁类药物在各时间点的镇痛效应均未达临床意义阈值。
  • 对术后慢性疼痛无预防作用,且头晕和视觉障碍风险增加。
  • 不推荐成人术后疼痛常规使用加巴喷丁或普瑞巴林。

核心结论

  • 围术期使用加巴喷丁类药物未观察到有临床意义的镇痛效果。
  • 对术后慢性疼痛无预防作用,且不良事件风险增加。
  • 结果不支持成人术后疼痛常规使用普瑞巴林或加巴喷丁。

研究设计与样本

  • 系统综述与荟萃分析,纳入研究加巴喷丁类药物用于成人手术的随机对照试验。
  • 共纳入281项试验,24682例参与者。
  • 主要结局为术后急性疼痛强度,次要结局包括亚急性疼痛、慢性疼痛、阿片类药物用量、住院时长及不良事件。

主要发现

  • 与对照相比,加巴喷丁类药物在6小时降低疼痛强度(100分制,平均差-10,95%CI -12至-9)。
  • 12小时平均差-9(95%CI -10至-7),24小时平均差-7(95%CI -8至-6),48小时平均差-3(95%CI -5至-1)。
  • 各时间点效应均低于最小重要差异阈值(100分制中10分),无临床意义。
  • 72小时疼痛、亚急性及慢性疼痛无影响。
  • 术后恶心呕吐风险降低,但头晕和视觉障碍增多。

关键数值与推荐

  • 疼痛强度采用100分制评估,最小重要差异阈值为10分。
  • 6小时平均差-10(95%CI -12至-9),12小时-9(95%CI -10至-7),24小时-7(95%CI -8至-6),48小时-3(95%CI -5至-1)。
  • 效应不受药物种类(加巴喷丁或普瑞巴林)影响。

临床怎么用

  • 成人术后急性疼痛管理中不应常规使用加巴喷丁或普瑞巴林。
  • 需权衡潜在的头晕和视觉障碍风险与有限的镇痛获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Widely used for acute pain management, the clinical benefit from perioperative use of gabapentinoids is uncertain. The aim of this systematic review was to assess the analgesic effect and adverse events with the perioperative use of gabapentinoids in adult patients. METHODS: Randomized controlled trials studying the use of gabapentinoids in adult patients undergoing surgery were included. The primary outcome was the intensity of postoperative acute pain. Secondary outcomes included the intensity of postoperative subacute pain, incidence of postoperative chronic pain, cumulative opioid use, persistent opioid use, lengths of stay, and adverse events. The clinical significance of the summary estimates was assessed based on established thresholds for minimally important differences. RESULTS: In total, 281 trials (N = 24,682 participants) were included in this meta-analysis. Compared with controls, gabapentinoids were associated with a lower postoperative pain intensity (100-point scale) at 6 h (mean difference, -10; 95% CI, -12 to -9), 12 h (mean difference, -9; 95% CI, -10 to -7), 24 h (mean difference, -7; 95% CI, -8 to -6), and 48 h (mean difference, -3; 95% CI, -5 to -1). This effect was not clinically significant ranging below the minimally important difference (10 points out of 100) for each time point. These results were consistent regardless of the type of drug (gabapentin or pregabalin). No effect was observed on pain intensity at 72 h, subacute and chronic pain. The use of gabapentinoids was associated with a lower risk of postoperative nausea and vomiting but with more dizziness and visual disturbance. CONCLUSIONS: No clinically significant analgesic effect for the perioperative use of gabapentinoids was observed. There was also no effect on the prevention of postoperative chronic pain and a greater risk of adverse events. These results do not support the routine use of pregabalin or gabapentin for the management of postoperative pain in adult patients.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Verret M, Lauzier F, Zarychanski R, et al. Perioperative Use of Gabapentinoids for the Management of Postoperative Acute Pain: A Systematic Review and Meta-analysis. Anesthesiology. 2020. PMID: 32667154. doi:10.1097/ALN.0000000000003428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。